Breckenridge Pharmaceutical, Inc. Enters into Multi-Product Agreement with Sam Chun Dang Pharm. Co., Ltd
July 03, 2017 at 12:59 pm EDT
Share
Breckenridge Pharmaceutical Inc. announced launch of multi-product agreement with Sam Chun Dang Pharm Co Ltd. (SCD), based in Seoul, Korea. As part of the agreement, Breckenridge and SCD expect to develop and commercialise at least seven ANDAs in South Korea for the US market. This agreement allows SCD to develop, manufacture and supply the products exclusively for Breckenridge for the US market, while Breckenridge will market and distribute the products in its label. Beginning in the first quarter of 2018, the partnership plans filing ANDAs for at least six ophthalmic products and one otic product. The total addressable IMS market value for this portfolio is USD 2.4 billion. This selection of products contributes to Breckenridge's Paragraph IV portfolio.
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Companyâs products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
SAM CHUN DANG PHARM. CO., LTD 
